HUP0003106A3 - Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma - Google Patents

Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Info

Publication number
HUP0003106A3
HUP0003106A3 HU0003106A HUP0003106A HUP0003106A3 HU P0003106 A3 HUP0003106 A3 HU P0003106A3 HU 0003106 A HU0003106 A HU 0003106A HU P0003106 A HUP0003106 A HU P0003106A HU P0003106 A3 HUP0003106 A3 HU P0003106A3
Authority
HU
Hungary
Prior art keywords
glaucoma
effects
treatment
prostaglandin derivatives
derivatives devoid
Prior art date
Application number
HU0003106A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0003106(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of HUP0003106A2 publication Critical patent/HUP0003106A2/hu
Publication of HUP0003106A3 publication Critical patent/HUP0003106A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0003106A 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma HUP0003106A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702706A SE9702706D0 (sv) 1997-07-11 1997-07-11 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Publications (2)

Publication Number Publication Date
HUP0003106A2 HUP0003106A2 (hu) 2001-01-29
HUP0003106A3 true HUP0003106A3 (en) 2002-12-28

Family

ID=20407743

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003106A HUP0003106A3 (en) 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Country Status (19)

Country Link
EP (1) EP1014991A1 (is)
JP (1) JP2002509543A (is)
KR (1) KR20010021682A (is)
CN (1) CN1169528C (is)
AU (1) AU739828B2 (is)
BR (1) BR9815501A (is)
CA (1) CA2294779A1 (is)
HK (1) HK1029942A1 (is)
HU (1) HUP0003106A3 (is)
IL (1) IL133871A (is)
IS (1) IS5333A (is)
NO (1) NO20000062D0 (is)
NZ (1) NZ501834A (is)
PL (1) PL337940A1 (is)
RU (1) RU2207858C2 (is)
SE (1) SE9702706D0 (is)
SK (1) SK183499A3 (is)
TR (1) TR200000008T2 (is)
WO (1) WO1999002165A1 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
AU2003299137A1 (en) * 2002-09-16 2004-04-23 Texas Tech University System Inhibition of metallo-beta-lactamase
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL212658B1 (pl) * 2005-04-18 2012-11-30 Inst Farmaceutyczny Sposób otrzymywania pochodnych 13,14-dihydro-PGF<sub>2</sub><sub>α</sub>
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JPWO2009133863A1 (ja) 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AU2009354014B2 (en) * 2009-10-16 2014-08-28 Cayman Chemical Company, Incorporated Process for the preparation of F-series prostaglandins
KR102070567B1 (ko) 2012-03-28 2020-01-29 메르크 파텐트 게엠베하 바이시클릭 피라지논 유도체
JP2012246301A (ja) * 2012-08-10 2012-12-13 Cayman Chemical Co Inc Ｆ系プロスタグランジン類を調製する方法
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002509543A (ja) 2002-03-26
AU739828B2 (en) 2001-10-18
NO20000062L (no) 2000-01-06
TR200000008T2 (tr) 2000-05-22
WO1999002165A1 (en) 1999-01-21
BR9815501A (pt) 2001-07-17
RU2207858C2 (ru) 2003-07-10
SE9702706D0 (sv) 1997-07-11
NO20000062D0 (no) 2000-01-06
EP1014991A1 (en) 2000-07-05
PL337940A1 (en) 2000-09-11
IL133871A0 (en) 2001-04-30
IL133871A (en) 2004-09-27
KR20010021682A (ko) 2001-03-15
CN1169528C (zh) 2004-10-06
CA2294779A1 (en) 1999-01-21
IS5333A (is) 2000-01-07
AU8368398A (en) 1999-02-08
CN1262623A (zh) 2000-08-09
SK183499A3 (en) 2000-07-11
HK1029942A1 (en) 2001-04-20
HUP0003106A2 (hu) 2001-01-29
NZ501834A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
IL133871A0 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
AU1520699A (en) Methods for treatment of disorders of cardiac contractility
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
HK1023119A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
HK1011933A1 (en) Indolinone compounds for the treatment of disease
AU6517196A (en) Piperazine derivatives as therapeutic agents
EP1007028A4 (en) TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
AU5436198A (en) 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
AU5258698A (en) 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
IL124382A0 (en) New process for the preparation of phenylimidazolidine derivatives
ZA9811531B (en) Novel process for the preparation of cyclosporin derivatives
IL117574A0 (en) Processes for the preparation of cyclobutanone derivatives
ZA976596B (en) Process for the catalytic preparation of n-acylglycine derivatives
HK1016965A1 (en) Process for the preparation of cyclopropylacetylene derivatives
HUP9903481A3 (en) Process for the preparation of 1-aryl-1-cyanocyclobutane derivatives
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
ZA981885B (en) Method for the preparation of alpha-bromo-lactam derivatives
AU2155995A (en) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU5699396A (en) Compositions for the treatment of skin conditions
PL317236A1 (en) Derivatives of naphtoquinone
AU7985698A (en) Methods for treatment of ocular neovascularization
HUP9601325A2 (en) Process for the preparation of optionally 2-substituted 5-chloroimidazole-4-carbaldehyde derivatives
SE9403186D0 (sv) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
HUP9901543A3 (en) Process for the preparation of hydroxysulfone derivatives
IL136949A0 (en) 1,4-diazacycloheptane derivatives for the treatment of neurological disorders